Lexeo Therapeutics, Inc. Common Stock (LXEO) Insider Trading
Over the last 3 months, LXEO insiders made 0 open-market buys and 3 sales, a net sale of -$337K (SEC Form 4). Over the last 6 months, 125 institutions increased and 63 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$336.7K
Insider trades by month Buys Sells
Aug
Oct
Nov
Feb
Apr
May
Context3-month price -37.8%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 20, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 3,342 | $5.06 |
| May 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 1,302 | $5.07 |
| Apr 30, 2026 | Sepp-Lorenzino Lauradirector | Grant | 50,000 | $5.81 |
| Apr 7, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 55,000 | $5.69 |
| Mar 17, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 2,623 | $2.64 |
| Mar 17, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 5,930 | $2.64 |
| Feb 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 721 | $9.27 |
| Feb 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 3,016 | $6.40 |
| Feb 20, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 10,173 | $6.38 |
| Feb 17, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 297,000 | $6.31 |
| Feb 17, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 49,500 | — |
| Feb 6, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 646,665 | $7.27 |
| Feb 6, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 65,000 | — |
| Feb 6, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 226,665 | $7.27 |
| Feb 6, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 44,665 | — |
| Feb 6, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 260,000 | $7.27 |
| Feb 6, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 161,665 | — |
| Nov 20, 2025 | Adler Ericofficer: Chief Medical Officer | Sell | 615 | $9.27 |
| Nov 20, 2025 | See Tai Sandiofficer: Chief Development Officer | Sell | 386 | $9.27 |
| Nov 20, 2025 | Robertson Jennyofficer: Chief Legal Officer | Sell | 549 | $9.27 |
| Nov 20, 2025 | Otero Jose Manuelofficer: Chief Technical Officer | Sell | 721 | $9.27 |
| Nov 20, 2025 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 1,127 | $9.27 |
| Oct 17, 2025 | Otero Jose Manuelofficer: Chief Technical Officer | Sell | 2,091 | $8.94 |
| Oct 17, 2025 | Otero Jose Manuelofficer: Chief Technical Officer | Sell | 24 | $9.56 |
| Oct 17, 2025 | Adler Ericofficer: Chief Medical Officer | Grant | 9,570 | — |
| Oct 17, 2025 | Adler Ericofficer: Chief Medical Officer | Sell | 3,344 | $8.94 |
| Oct 17, 2025 | Adler Ericofficer: Chief Medical Officer | Sell | 38 | $9.56 |
| Oct 17, 2025 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 33,000 | — |
| Oct 17, 2025 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 12,985 | $8.94 |
| Oct 17, 2025 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 148 | $9.56 |
Source: LXEO SEC Form 4 filings, latest May 20, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their LXEO positions over the last 6 months (SEC Form 13F).
Increased
125
New positions
63
Reduced
63
Sold out
36
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 6.2M | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 5.5M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 5.1M | May 13, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 5.1M | May 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 5.0M | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 5.0M | Feb 17, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 5.0M | May 18, 2026 |
| BLACKROCK, INC. | Increased | 4.9M | Feb 12, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | New Position | 4.8M | Feb 17, 2026 |
| VESTAL POINT CAPITAL, LP | Unchanged | 4.5M | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Increased | 4.5M | Feb 17, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4.4M | Feb 13, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4.4M | May 15, 2026 |
| VANGUARD GROUP INC | Increased | 3.9M | Jan 29, 2026 |
| CITADEL ADVISORS LLC | Increased | 3.8M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.